Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma
Authors:
- Cindy A. SanderCSCindy A. Sander
- Wenjun WangWWWenjun Wang
- Shelley L. ReppertSRShelley L. Reppert
- Laura M. DrogowskiLDLaura M. Drogowski
- Drazen M. JukicDJDrazen M. Jukic
- Uma N. M. RaoURUma N. M. Rao
- Charalambos AthanassiouCACharalambos Athanassiou
- Manuela BuzoianuMBManuela Buzoianu
- Maja MandicMMMaja Mandic
- Laura RichmanLRLaura Richman
- LuAnn McKinneyLMLuAnn McKinney
- 1 April 2010
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 33 (3) , 316-325
Abstract
AlphaVbeta3 (alphavbeta3) is an important molecule for tumor-induced angiogenesis and is upregulated in metastatic melanoma (MM). We proposed to study the mechanism of action of etaracizumab, a monoclonal antibody targeting alphavbeta3, in MM. Patients with MM and biopsiable tumor were treated with etaracizumab in 3 dose cohorts starting from 8 mg/kg. Tumor saturation by etaracizumab using LM609 immunohistochemical staining of tumor sections was the primary endpoint. Subsequent dose cohorts were defined based on the tumor saturation by etaracizumab. Secondary end points were analysis of clinical benefit and changes from baseline of several tumor and peripheral blood biomarkers. Eighteen patients were enrolled at 3 dose levels. Etaracizumab showed better melanoma cell saturation at the 8mg/kg and 1 mg/kg dose compared with the 4 mg/kg dose and better vascular endothelial cell saturation at 8 mg/kg compared with lower dose groups. Etaracizumab demonstrated an acceptable safety profile. The optimal biologic dose out of those selected for investigation was 8 mg/kg. Patients treated at the highest dose may have had better clinical benefit secondary to suppression of the activated immediate downstream effector of alphavbeta3 signaling, FAK, in melanoma cells, but this alone did not ultimately affect melanoma cell proliferation or apoptosis. No apparent antiangiogenic or immunomodulatory effects of etaracizumab were noted.Keywords
This publication has 24 references indexed in Scilit:
- Designing Phase 0 Cancer Clinical TrialsClinical Cancer Research, 2008
- Integrins in angiogenesis and lymphangiogenesisNature Reviews Cancer, 2008
- Overcoming apoptosis deficiency of melanoma—Hope for new therapeutic approachesDrug Resistance Updates, 2007
- Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™Molecular Cancer Therapeutics, 2006
- The role of N-Cadherin, MCAM, and β3 integrin in melanoma progression, proliferation, migration and invasionCancer Biology & Therapy, 2006
- Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by α v β 3 integrin signalingCarcinogenesis, 2006
- Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor PerfusionClinical Cancer Research, 2005
- Adhesion, migration and communication in melanocytes and melanomaPigment Cell Research, 2005
- Melanoma2005
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994